Can drug screening lead to candidate therapies for testing in diabetic neuropathy?

Antioxidants and Redox Signaling

Volumn 10, Issue 2, 2008, Pages 387-393

  Vincent, Andrea M ^a   Feldman, Eva L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOHIPPURIC ACID; ATENOLOL; BENAZEPRIL; BEPRIDIL; BETAMIPRON; CAFFEINE; CARNITINE; CETYLPYRIDINIUM SALT; CLEMASTINE; ECDYSTERONE; ERGOCALCIFEROL; FENOFIBRATE; GENTAMICIN; GLUCOSE; GOSSYPOL; HOMOTAURINE; ISOPRENALINE; MECLOZINE; MINOXIDIL; MORIN; NEOCOBEFRIN; PACLITAXEL; PHENYLMERCURIC ACETATE; PIPERAZINE; PRAZIQUANTEL; PROTIONAMIDE; ROXARSONE; SUPEROXIDE; SUPROFEN; UNINDEXED DRUG;

DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE SEVERITY; DRUG DESIGN; DRUG SCREENING; HUMAN; HYPERGLYCEMIA; MITOCHONDRION; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SENSORY NERVE CELL; SHORT SURVEY; SPINAL GANGLION; VALIDATION PROCESS;

ANIMALS; DIABETIC NEUROPATHIES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; HYPERGLYCEMIA; MITOCHONDRIA; OXIDATIVE STRESS;

EID: 37549059139     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2007.1815     Document Type: Short Survey

References (29)

1. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820, 2001.
2. Brussee V, Cunningham FA, and Zochodne DW. Direct insulin signaling of neurons reverses diabetic neuropathy. Diabetes 53: 1824-1830, 2004.
3. Collins CD, Purohit S, Podolsky RH, Zhao HS, Schatz D, Eckenrode SE, Yang P, Hopkins D, Muir A, Hoffman M, McIndoe RA, Rewers M, and She JX. The application of genomic and proteomic technologies in predictive, preventive and personalized medicine. Vascul Pharmacol 45: 258-267, 2006.
4. Gottlieb M, Leal-Campanario R, Campos-Esparza MR, Sanchez-Gomez MV, Alberdi E, Arranz A, Gado-Garcia JM, Gruart A, and Matute C. Neuroprotection by two polyphenols following excitotoxicity and experimental ischemia. Neurobiol Dis 23: 374-386, 2006.
5. Harano Y, Yasui K, Toyama T, Nakajima T, Mitsuyoshi H, Mimani M, Hirasawa T, Itoh Y, and Okanoue T. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver Int 26: 613-20, 2006.
6. Hosseinzadeh H, Nassiri AM, and Parvardeh S. The effects of carbenoxolone, a semisynthetic derivative of glycyrrhizinic acid, on peripheral and central ischemia-reperfusion injuries in the skeletal muscle and hippocampus of rats. Phytomedicine 12: 632-637, 2005
7. Kishi M, Mitsui M, Nagamatsu M, Nickander KK, Schmelzer JD, Tanabe J, Yao JK, and Low PA. Dorsal root ganglion pathology in chronic experimental diabetic neuropathy. J Periph Nerv Syst 6: 152-153, 2001
8. Kocer I, Taysi S, Ertekin MV, Karslioglu I, Gepdiremen A, Sezen O, and Serifoglu K. The effect of L-carnitine in the prevention of ionizing radiation-induced cataracts: a rat model. Graefes Arch Clin Exp Ophthalmol 245: 588-594, 2007.
9. Malone JI, Cuthbertson DD, Malone MA, and Schocken DD. Cardio-protective effects of carnitine in streptozotocin-induced diabetic rats. Cardiovasc Diabetol 5: 2, 2006.
10. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, and Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. J Am Med Assoc 295: 1681-1687, 2006.
11. Okopien B, Krysiak R, and Herman ZS. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab 91: 1770-1778, 2006.
12. Park CW, Zhang Y, Zhang X, Wu J, Chen L, Cha DR, Su D, Hwang MT, Fan X, Davis L, Striker G, Zheng F, Breyer M, and Guan Y. PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney International 69: 1511-1517, 2006.
13. Pop-Busui R, Marinescu V, Van Huysen C, Li F, Sullivan K, Greene DA, Larkin D, and Stevens MJ. Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration. Diabetes 51: 2619-2628, 2002.
14. Russell JW, Golovoy D, Vincent AM, Mahendru P, Olzmann JA, Mentzer A, and Feldman EL. High glucose induced oxidative stress and mitochondrial dysfunction in neurons. FASEB J 16: 1738-1748, 2002.
15. Russell JW, Sullivan KA, Windebank AJ, Herrmann DN, and Feldman EL. Neurons undergo apoptosis in animal and cell culture models of diabetes. Neurobiol Dis 6: 347-363, 1999.
16. Schmeichel AM, Schmelzer JD, and Low PA. Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 52: 165-171, 2003.
17. Sullivan KA and Feldman EL. New developments in diabetic neuropathy. Current Opinion in Neurology 18: 586-590,2005.
18. Varghese Z, Moorhead JF, and Ruan XZ. The PPARalpha ligand fenofibrate: meeting multiple targets in diabetic nephropathy. Kidney Intern 69: 1490-1491, 2006.
19. Vincent AM, Backus C, Taubman AA, and Feldman EL. Identification of candidate drugs for the treatment of ALS. Amyo Lat Scler 6: 29-36, 2005.
20. Vincent AM, McLean LL, Backus C, and Feldman EL. Short-term hyperglycemia produces oxidative damage and apoptosis in neurons. FASEB J 19: 638-640, 2005.
21. Vincent AM, Mobley BC, Hiller A, and Feldman EL. IGF-I prevents glutamate-induced motor neuron programmed cell death. Neurobiol Dis 16: 407-416, 2004.
22. Vincent AM, Olzmann JA, Brownlee M, Sivitz WI, and Russell JW. Uncoupling proteins prevent glucose-induced neuronal oxidative stress and programmed cell death. Diabetes 53: 726-734, 2004.
23. Vincent AM, Russell JW, Low P, and Feldman EL. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocrine Rev 25: 612-628, 2004.
24. Vincent AM, Russell JW, Sullivan KA, Backus C, Hayes JM, McLean LL, and Feldman EL. SOD2 protects neurons from injury in cell culture and animal models of diabetic neuropathy. Exp Neurol (in press).
25. Vincent AM, Stevens MJ, Backus C, McLean LL, and Feldman EL. Cell culture modeling to test therapies against hyperglycemia-mediated oxidative stress and injury. Antioxid Redox Signal 7: 1494-1506, 2005.
26. Vinik A, Ullal J, Parson HK, and Casellini CM. Diabetic neuropathies: clinical manifestations and current treatment options. Nat Clin Pract Endocrinol Metab 2: 269-281, 2006.
27. Wang Y, Schmeichel AM, Iida H, Schmelzer JD, and Low PA. Enhanced inflammatory response via activation of NF-kappaB in acute experimental diabetic neuropathy subjected to ischemia-reperfusion injury. J Neurol Sci 247: 47-52, 2006.
28. Wierzbicki AS. FIELDS of dreams, fields of tears: a perspective on the fibrate trials. Int J Clin Pract 60: 442-449, 2006.
29. Wing LK, Behanna HA, Van Eldik LJ, Watterson DM, and Ralay RH. De novo and molecular target-independent discovery of orally bioavailable lead compounds for neurological disorders. Curr Alzheimer Res 3: 205-214, 2006.